Interesting analysis of the haemophilia R and D and opportunities for CSL
Target price $60
"Products to boost earnings by 7.5%, but potentially up to 30%: For each market segment we have examined a range of scenarios, based on the outcome of key clinical trials. Using what we think are conservative assumptions, we calculate a probability-weighted impact of +7.5% for CSL from its R&D haemophilia portfolio. If, however, CSL is successful in bringing its factor 7a, 8 and 9 to market, we believe earnings will increase by +29%."
http://www.macquarie.com.au/dafiles/Internet/mgl/au/apps/retail-newsletter/docs/2012_12/CSL171212e.pdf
Interesting analysis of the haemophilia R and D and...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.21 |
Change
0.050(0.02%) |
Mkt cap ! $142.6B | |||
| Open | High | Low | Value | Volume |
| $296.30 | $298.20 | $295.00 | $229.6M | 780.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248 | $295.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.21 | 42 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |